生物补片与合成补片单期修复污染性腹壁疝的随机临床试验
这项多中心、单盲随机临床试验纳入253例清洁-污染或污染性腹壁疝患者,比较后鞘合成补片与生物补片单期修复的效果。结果显示合成补片显著降低2年疝复发风险(HR 0.31),两组需干预的手术部位并发症无显著差异,但生物补片组30天住院直接费用和假体费用显著更高。
要点
- 合成补片较生物补片显著降低2年疝复发风险(HR 0.31,95%CI 0.23-0.42)。
- 两组需干预的手术部位并发症风险无显著差异(OR 1.22,95%CI 0.60-2.44)。
- 生物补片组30天住院直接费用和假体费用均显著高于合成补片组。
核心结论
- 在污染性腹壁疝单期修复中,合成补片较生物补片显著降低2年疝复发风险,且两者安全性相似。
- 生物补片价格超过合成补片的200倍。
研究设计与样本
- 多中心、单盲随机临床试验,2012年12月至2019年4月在美国5个学术医学中心完成,随访2年。
- 共纳入253例清洁-污染或污染性腹壁疝成人患者,随机分为合成补片组126例和生物补片组127例,2年随访率92%。
- 主要结局为基于意向性治疗分析的2年疝复发风险优效性,次要结局包括需干预的手术部位并发症和30天住院直接费用及假体费用。
主要发现
- 总体意向性治疗2年疝复发风险为13%(33/253)。
临床怎么用
- 对于清洁-污染或污染性腹壁疝单期修复,合成补片可显著降低2年疝复发风险,且安全性相似,费用显著更低。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Biologic mesh is widely used for reinforcing contaminated ventral hernia repairs; however, it is expensive and has been associated with high rates of long-term hernia recurrence. Synthetic mesh is a lower-cost alternative but its efficacy has not been rigorously studied in individuals with contaminated hernias. OBJECTIVE: To determine whether synthetic mesh results in superior reduction in risk of hernia recurrence compared with biologic mesh during the single-stage repair of clean-contaminated and contaminated ventral hernias. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, single-blinded randomized clinical trial was conducted from December 2012 to April 2019 with a follow-up duration of 2 years. The trial was completed at 5 academic medical centers in the US with specialized units for abdominal wall reconstruction. A total of 253 adult patients with clean-contaminated or contaminated ventral hernias were enrolled in this trial. Follow-up was completed in April 2021. INTERVENTIONS: Retromuscular synthetic or biologic mesh at the time of fascial closure. MAIN OUTCOMES AND MEASURES: The primary outcome was the superiority of synthetic mesh vs biologic mesh at reducing risk of hernia recurrence at 2 years based on intent-to-treat analysis. Secondary outcomes included mesh safety, defined as the rate of surgical site occurrence requiring a procedural intervention, and 30-day hospital direct costs and prosthetic costs. RESULTS: A total of 253 patients (median [IQR] age, 64 [55-70] years; 117 [46%] male) were randomized (126 to synthetic mesh and 127 to biologic mesh) and the follow-up rate was 92% at 2 years. Compared with biologic mesh, synthetic mesh significantly reduced the risk of hernia recurrence (hazard ratio, 0.31; 95% CI, 0.23-0.42; P < .001). The overall intent-to-treat hernia recurrence risk at 2 years was 13% (33 of 253 patients). Recurrence risk with biologic mesh was 20.5% (26 of 127 patients) and with synthetic mesh was 5.6% (7 of 126 patients), with an absolute risk reduction of 14.9% with the use of synthetic mesh (95% CI, -23.8% to -6.1%; P = .001). There was no significant difference in overall 2-year risk of surgical site occurrence requiring a procedural intervention between the groups (odds ratio, 1.22; 95% CI, 0.60-2.44; P = .58). Median (IQR) 30-day hospital direct costs were significantly greater in the biologic group vs the synthetic group ($44 936 [$35 877-$52 656] vs $17 289 [$14 643-$22 901], respectively; P < .001). There was also a significant difference in the price of the prosthetic device between the 2 groups (median [IQR] cost biologic, $21 539 [$20 285-$23 332] vs synthetic, $105 [$105-$118]; P < .001). CONCLUSIONS AND RELEVANCE: Synthetic mesh demonstrated superior 2-year hernia recurrence risk compared with biologic mesh in patients undergoing single-stage repair of contaminated ventral hernias, and both meshes demonstrated similar safety profiles. The price of biologic mesh was over 200 times that of synthetic mesh for these outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02451176.
引用
- Rosen MJ, Krpata DM, Petro CC, et al. Biologic vs Synthetic Mesh for Single-stage Repair of Contaminated Ventral Hernias: A Randomized Clinical Trial. JAMA Surg. 2022. PMID: 35044431. doi:10.1001/jamasurg.2021.6902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。